Stock 600488 TIANJIN TIANYAO PHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Tianjin Tianyao Pharmaceuticals Co., Ltd.

Equities

600488

CNE000001840

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
3.91 CNY +0.51% Intraday chart for Tianjin Tianyao Pharmaceuticals Co., Ltd. +5.39% -20.20%
Apr. 25 Jinyao Pharma's Unit Gets Approval to Market Compound Ipratropium Bromide Solution MT
Mar. 28 Tianjin Tianyao Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 4,073 4,542 5,427 5,051 4,835 5,360
Enterprise Value (EV) 1 4,514 5,186 6,465 6,226 5,591 5,593
P/E ratio 26.5 x 31.3 x 159 x 102 x 138 x 45.8 x
Yield 1.5% 0.96% 0.2% 0.31% 0.23% 1.78%
Capitalization / Revenue 1.68 x 1.56 x 1.74 x 1.35 x 1.31 x 1.42 x
EV / Revenue 1.86 x 1.78 x 2.07 x 1.66 x 1.52 x 1.48 x
EV / EBITDA 12.1 x 12.2 x 18.6 x 16.2 x 13.1 x 12.8 x
EV / FCF -9.58 x -121 x 196 x -79.9 x 13.1 x 11.6 x
FCF Yield -10.4% -0.83% 0.51% -1.25% 7.65% 8.63%
Price to Book 1.44 x 1.56 x 1.81 x 1.69 x 1.63 x 1.81 x
Nbr of stocks (in thousands) 1,091,887 1,091,887 1,100,787 1,100,347 1,096,363 1,093,933
Reference price 2 3.730 4.160 4.930 4.590 4.410 4.900
Announcement Date 3/27/19 3/25/20 4/15/21 3/29/22 3/29/23 3/28/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 2,428 2,916 3,117 3,749 3,689 3,783
EBITDA 1 372.6 425.8 347.4 383.2 426.8 437.8
EBIT 1 266.1 285.6 166.4 178.2 181.3 179.9
Operating Margin 10.96% 9.8% 5.34% 4.75% 4.91% 4.76%
Earnings before Tax (EBT) 1 230.6 253 112.4 149.1 12.52 168.2
Net income 1 153.5 145.3 33.98 48.67 35.41 117.1
Net margin 6.32% 4.98% 1.09% 1.3% 0.96% 3.09%
EPS 2 0.1405 0.1330 0.0310 0.0450 0.0320 0.1070
Free Cash Flow 1 -471.4 -42.79 33.03 -77.93 427.8 482.6
FCF margin -19.42% -1.47% 1.06% -2.08% 11.6% 12.76%
FCF Conversion (EBITDA) - - 9.51% - 100.23% 110.23%
FCF Conversion (Net income) - - 97.2% - 1,208.2% 412.3%
Dividend per Share 2 0.0560 0.0400 0.0100 0.0140 0.0100 0.0870
Announcement Date 3/27/19 3/25/20 4/15/21 3/29/22 3/29/23 3/28/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 441 644 1,039 1,175 756 233
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 1.185 x 1.512 x 2.989 x 3.067 x 1.77 x 0.5324 x
Free Cash Flow 1 -471 -42.8 33 -77.9 428 483
ROE (net income / shareholders' equity) 6.14% 5.33% 2.14% 2.86% 0.49% 4.33%
ROA (Net income/ Total Assets) 3.66% 3.41% 1.75% 1.78% 1.74% 1.76%
Assets 1 4,191 4,258 1,942 2,736 2,031 6,658
Book Value Per Share 2 2.600 2.670 2.720 2.720 2.710 2.700
Cash Flow per Share 2 0.3100 0.2300 0.2200 0.2100 0.5900 0.6600
Capex 1 204 279 459 371 202 133
Capex / Sales 8.39% 9.57% 14.71% 9.89% 5.48% 3.52%
Announcement Date 3/27/19 3/25/20 4/15/21 3/29/22 3/29/23 3/28/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
TIANJIN TIANYAO PHARMACEUTICALS CO., LTD. Stock Tianjin Tianyao Pharmaceuticals Co., Ltd.
-20.20% 590M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 600488 Stock
  4. Financials Tianjin Tianyao Pharmaceuticals Co., Ltd.